Gastric Cancer | Specialty

First-Line Cadonilimab Plus Chemo Wins Approval in China for Advanced Gastric/GEJ Adenocarcinoma

September 30th 2024

Cadonilimab plus chemotherapy has been approved in China for first-line locally advanced or metastatic gastric/GEJ adenocarcinoma.

ODAC Votes Against Risk:Benefit Profile of Frontline PD-1 Inhibitors in HER2–, MSS Gastric/GEJ Adenocarcinoma With a PD-L1 Expression Under 1

September 26th 2024

The FDA’s ODAC voted against the risk:benefit profile of PD-1 inhibitors in first-line advanced gastric/GEJ adenocarcinoma with a PD-L1 of less than 1.

Dr Strickler on the Safety and Efficacy of Telisotuzumab Adizutecan in Gastric/GEJ Cancer

September 25th 2024

John H. Strickler, MD, discusses the efficacy and safety of telisotuzumab adizutecan in patients with MET gene–amplified gastric/GEJ cancer.

Pembrolizumab Improves Survival for Gastric/GEJ Adenocarcinoma

September 14th 2024

Pembrolizumab plus trastuzumab and chemotherapy reduced the risk of death by 20% in patients with advanced, unresectable, or metastatic HER2+ gastric or GEJ cancer.

Dr Eads on the Rationale for ECOG-ACRIN EA2174 in Esophageal/GEJ Adenocarcinoma

September 11th 2024

Jennifer R. Eads, MD, discusses the evaluation of the addition of nivolumab to neoadjuvant chemotherapy and radiation in esophageal/GEJ adenocarcinoma.

sNDA Withdrawn for Fruquitinib Plus Paclitaxel in Second-Line Gastric Cancer in China

August 30th 2024

The supplemental new drug application for fruquintinib plus paclitaxel in second-line gastric cancer in China has been voluntarily withdrawn.

Dr Bekaii-Saab on the Benefits of Multidisciplinary Conferences in GI Cancer Care

August 7th 2024

Tanios Bekaii-Saab, MD, FACP, discusses the benefits of multidisciplinary conferences within the gastrointestinal cancer treatment field.

Two Leading Experts Detail Hot Topics in GI Cancers to Be Presented at Upcoming ISGIO Meeting

July 31st 2024

Eileen M. O’Reilly, MD, and Tanios S. Bekaii-Saab, MD, FACP, discuss key topics in gastrointestinal cancer to be presented during the 2024 ISGIO Meeting.

Revisit Every OncLive On Air Episode From June 2024

July 1st 2024

In case you missed any, below is a recap of every OncLive On Air episode that aired in June 2024.

Dr Kelly on ctDNA Dynamics Following Neoadjuvant Immunotherapy in GEJ Cancer

May 20th 2024

Ronan J. Kelly, MD, MBA, FASCO, discusses the predictive value of ctDNA following neoadjuvant immunotherapy in resectable gastroesophageal cancer.